As the leading Cancer Centre in Europe, Gustave Roussy is ranked among the ten world leaders in oncology research and patient care.

The Institute treats patients with every type of cancer at any age and is expert in the treatment of rare and complex tumours.

The Gustave Roussy units share the values of regard for the individual, creativity, daring inventiveness and collaboration. They respond to a continuing challenge: to deliver to patients the fruits of the most recent advances.

Gustave Roussy embarked in 2018 on an investment plan on an unprecedented scale which aims to continue acquiring the latest equipment and to increase the number of patients we can treat, so that we maintain our innovation at the highest level and deliver it to the greatest number. Gustave Roussy will be investing a total of 250 M€ to modernise the Institute over the period up to 2024. It is at the heart of the plans for the overall re-development of the “Campus Grand Parc”. In 2021, Gustave Roussy will open a new building of more than 11,000 m² connected to the old one. It will incorporate a Day Hospital and a Wellness Centre.

Our ambition is immense: extending the frontiers of science, continuously reinventing methods of treatment of patients and exploring every source of innovation.

Our doctors and researchers devote their energies and their skills to this great challenge: to speed up progress in order to expand the limits of knowledge and offer patients continuing improvements in the specificity of their treatment. And to raise the hope of curing cancer in the 21st century.
CONDUCTING DARING RESEARCH

Gustave Roussy is always in the vanguard of progress. It brings together the best workers in fundamental, clinical and translational research. Very close collaboration between research scientists and doctors means that patients get access in the shortest possible time to the very latest developments in treatment.

Through the impact of its scientific articles and the presence of its researchers at international conferences, Gustave Roussy proves the effectiveness of its model as an integrated centre for research and clinical practice. The activities of the Institute’s research units are concentrated on personalised medicine, immunotherapy, DNA repair and artificial intelligence.

A GUSTAVE ROUSSY UNIVERSITY HOSPITAL INSTITUTE OF PRECISION MEDICINE

In 2018, the Prism project at Gustave Roussy was designated as a University Hospital Institute. This is a collaboration between Inserm, CentraleSupélec, the Paris-Sud University, Unicancer and the ARC (Association for Cancer Research) Foundation. This second generation oncological precision medicine institute is coordinated by Professor Fabrice André and its goal is to model cancer at the individual level in order to select the most appropriate medication for each patient. Prism will be conducting large-scale clinical studies and developing techniques for molecular and data analysis.

74 M€
dedicated to research

304
international publications with an impact factor > 10 (excluding conferences)

72
trials sponsored by Gustave Roussy of which 9 in Precision Medicine Programme

27 %
of the patients treated in 2018 were involved in a clinical research

241
clinical trials in immunotherapy since 2013, of which 64 in 2018

518
patients included in phases I and I/II trials

4,895
Gustave Roussy patients have participated in the Precision Medicine Programme since 2011

469
clinical trials in 2018
Gustave Roussy is committed to being the engine of rapid progress in oncology, whether in terms of therapy or care pathways. Employing novel methods of caring for individual patients in the least invasive way possible and by ensuring that this takes place in the safest way, the Institute is giving cancer patients high quality care from the time of diagnosis on through their treatment.

As a university hospital institute, Gustave Roussy disposes of a full therapeutic arsenal for its patients: immunotherapy, chemotherapy, radiotherapy, interventional radiology, DNA sequencing, oncological and reparative surgery, etc. Its infrastructure functions at the highest level: surgical robots, a day surgery department, radiosurgery, brachytherapy, robotic chemotherapy drug preparation systems, genomics, etc.

Gustave Roussy is positioned today in the first European rank for early trials with a dedicated Drug Development Department (Ditep) to facilitate patient access to new medicines. Whereas the mean numbers of cancer patients recruited to a clinical trial in France lie between 4 and 10%, the figure for Gustave Roussy patients participating in such research is 27%.

<table>
<thead>
<tr>
<th>223,500</th>
<th>53,000</th>
<th>19,400</th>
</tr>
</thead>
<tbody>
<tr>
<td>medical consultations</td>
<td>ambulatory stays (excluding radiotherapy)</td>
<td>hospital stays</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4,052</th>
<th>655</th>
<th>6,093</th>
</tr>
</thead>
<tbody>
<tr>
<td>patients treated by radiotherapy and 62,300 sessions</td>
<td>patients treated by tomotherapy and 16,214 sessions</td>
<td>patients treated with chemotherapy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5,850</th>
<th>269</th>
<th>2,408</th>
</tr>
</thead>
<tbody>
<tr>
<td>new patients admitted to standard wards</td>
<td>stem cell transplantations of which 62 in paediatrics</td>
<td>patients treated by interventional radiology</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>92%</th>
</tr>
</thead>
<tbody>
<tr>
<td>bed occupancy rate</td>
</tr>
</tbody>
</table>
PASSING ON KNOWLEDGE

Gustave Roussy fulfils a mission to teach and pass on its oncological expertise to train doctors, research scientists, nurses, students and all health professional looking after cancer patients. These high grade educational programmes are delivered by recognised experts, actively engaged in making advances in the field and they facilitate the rapid spread of new therapies and constantly developing knowledge.

The École des sciences du cancer was set up in 2012 by Gustave Roussy and Paris-Sud University. It is the only such establishment in France. Its high level teaching body educates students for the new types of posts in oncology with courses leading to degrees and other qualifications.

The École has developed a model of teaching focused on pictorial and digital presentations and interaction with the student: a website for digital forms of teaching complements the École’s teaching tools.

In addition, the École doctorale en cancérologie, the only doctoral school in France with the single theme of oncology, comprises 85 research units and welcomes 55 new doctoral students per year.

- 551 practitioners teaching in the École des sciences du cancer, 204 of them from Gustave Roussy
- 26 university teachers
- 26 university diplomas & 2 masters
- 10,000 registered students on the digital learning platform of the École des sciences du cancer
- 245 doctoral students in the École doctorale de cancérologie
- 200,000 articles and e-books downloaded, from the stock of 3,559 e-books and 600 journals
- 60,000 hours devoted to training, 6,000 of those being at university level
- 40 scientific seminars and master classes
The Institute is a “private establishment of collective benefit” and, just like the Gustave Roussy Research Foundation, is authorised to receive donations and bequests. Public generosity forms an essential support for our research units and care departments, acting as a real stimulus to progress by giving Gustave Roussy staff the means to advance in the fight against cancer in fundamental, clinical and translational research and by improving patients’ quality of life.


The “Curing cancer in the 21st century” campaign fund reached 32 M€ in 2018 and the campaign for research in paediatric oncology continues to do well with overall funds of 5.5 M€.

An increase of 4% in funds raised in a sector which is doing badly elsewhere (50% mean reduction for some foundations and charitable associations) shows that the French feel concern for medical research, especially in cancer. They are choosing to donate to Gustave Roussy as the best way to achieve a cure for cancer.

In 2018, Gustave Roussy and its Foundation benefitted from the renewal of accreditation for “Donate in confidence” which certifies that donations are handled transparently and used properly.
GUSTAVE ROUSSY AT A GLANCE

- **427 beds** & **124 places in day hospital**
- **48,000 patients seen in in-clinic** of whom **11,000 had their first appointment**
- **53,000 ambulatory stays** (excluding radiotherapy)
- **19,400 hospital stays in full admission**
- **396,1 M€ overall budget**
- **27% of the patients treated in 2018 were involved in a clinical research**
- **64 international publications with an IF >30**
- **3,100 employees**
- **3,300 students and practitioners trained, and 6,700 trained online**
- **1,200 nursing staff**
- **950 research staff**
- **520 medical staff and 446 full-time equivalent**
- **34 research teams and 10 research units**
- **74 patent families**
“

We are putting Gustave Roussy in marching order to pursue its mission by anticipating today how patients will be cared for tomorrow.”

Professor Alexander Eggermont
General Director

www.gustaveroussy.fr

114, rue Édouard-Vaillant
94805 Villejuif Cedex - France